Tracking 6 vendors · 83 listings · checked Aug 02Current partner codePEPTIDESDE

Industry sponsor intelligence

BayerClinical Pipeline.

Lead-sponsor view of Bayer's indexed peptide studies, development phases, active programs, completed work and recent registry changes.

Total: 1
Recruiting: 1
Active: 0
Completed: 0
Results posted: 0
Avg enrollment: 250

Pipeline overview

Programs by phase and activity.

Velocity

Bayer trials by start year

Study start year · indexed snapshot

Development

Trials by phase

1phase labels

Early Phase 10

Phase 10

Phase 21

Phase 30

Phase 40

Product	Studies	Early / I	Phase II	Phase III	Phase IV	Active
Goserelin →	1	0	1	0	0	1

Active peptide trials

In motion now.

NCT IDStudyPhase / statusEnrollmentUpdated

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.

Bayer · High-Risk Localized Prostate Cancer

Phase 2

Recruiting

250

2026-06

Completed trials

Finished registry records.

No studies in this snapshot.

Search sponsor records

All Bayer studies.

This page groups studies where Bayer is listed as the lead industry sponsor. Collaborator-only records are not included in the count.

1 matching study

Last registry update first

NCT07450599Phase 2

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.

GoserelinBayerHigh-Risk Localized Prostate Cancer

Enrollment: 250
Started: Apr 2026
Completion: Oct 2030
Locations: 23
Countries: 1
Updated: Jun 2026

End of 1 results

Recent updates

Latest registry movement.

NCT07450599A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.Jun 24, 2026